0001035354 false 0001035354 2023-09-15 2023-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

  

FORM 8-K

 

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 15, 2023

 

 

 

Eloxx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

  

Delaware   001-31326   84-1368850

(State or other jurisdiction
of incorporation)

  

(Commission File Number)

  

(I.R.S. Employer

Identification No.)

 

480 Arsenal Way, Suite 130, Watertown, MA

   02472
(Address of principal executive offices)   (Zip Code)

 

(Registrant’s telephone number, including area code): (781) 577-5300

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, $0.01 par value per share ELOX The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On September 15, 2023, Dr. Vijay Modur, Head of Research and Development of Eloxx Pharmaceuticals, Inc. (the “Company”), notified the Company of his resignation effective September 30, 2023.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 15, 2023 ELOXX PHARMACEUTICALS, INC.
   
  By:  /s/ Sumit Aggarwal
  Name: Sumit Aggarwal
  Title: President and Chief Executive Officer

 

 

 

v3.23.2
Cover
Sep. 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 15, 2023
Entity File Number 001-31326
Entity Registrant Name Eloxx Pharmaceuticals, Inc.
Entity Central Index Key 0001035354
Entity Tax Identification Number 84-1368850
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 480 Arsenal Way, Suite 130
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 781
Local Phone Number 577-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol ELOX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Eloxx Pharmaceuticals Charts.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Eloxx Pharmaceuticals Charts.